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We investigated whether the histopathological effect (cell viability) of neoadjuvant hormonal 
treatment before radical prostatectomy for clinically localized prostate cancer is involved in the 
biochemical outcome， i.e.， androgen independency. Non-randomized prospective trial was carried out 
between September 1996 and April2001 involving the patients with clinical stage TI-3 prostate cancer， 
including 62 who underwent radical prostatectomy after receiving neoadjuvant hormonal treatment for 
an average of 6.3 months and 76 who underwent radical prostectomy only. All resected specimens 
were histopathologically diagnosed by whole section analysis. The patients receivi昭 neoadjuvant
hormonal treatment were categorized into 4-groups according to the histological change in the resected 
prostate. There were 8 patients in GO (al viable cells) ， 11 patients in G 1 (more than 50% viable 
cells)， 26 patients G2 (more than 50% non-viable cells) and 17 patients in G3 (no cancer cells). No 
difference in the patient background (prostate specffic antigen， stage， Gleason score， positive core Nr， 
duration of neoadjuvant therapy) was observed in any group， except for the duration of (p<0.05). 
Multivariate hazards analyses revealed that only the duration ofneoadjuvant hormonal treatment was 
independently associated with excellent responders with grade 3 histological effect. Neoadju町van
hormonal t白herapyprior to radical operation resulted in various histωopa剖tholog伊icalchanges in the 
P戸ro凶st凶at旬e，but it is not clear whether t出hehistological ef妊fect匂sof hormonal treatment might be involved in 
the outcome. A longer follow-up randomized prospective trial is necessary. 
(Acta Urol. Jpn. 48: 719-723， 2002) 



























Histological effects with respect to 
Clinical stage 





G3/excellent responder (n= 17); G2/good responder 
(n=26); GO， Gl/poor responder (n=19) Excel vs. 






























G3/excellent responder (n=17); G2/good responder 
(n=26) ; GO， G l/poor responder (n= 19) Excel vs. Poor: 









Histological effect with respect to pre-
operative PSA. 
ト療法の poorresponder (grade 1/0)に highstage 
の症例が若干多い傾向が認められた (Table2， 3). 
次に手術直前の血清 PSA値と組織学的治療効果と
を比較すると，当然のことながら excellentrespon-















Tl/2 : 39例， T3: 23例，コントロール群において













治療効果は grade0: 7例， grade 1 : 1例， grade 


















をexcellentresponder， grade 2をgoodresponder， 
grade 1/0をpoorresponderとして解析した.
また，解析ソフトは Stat-View 5.0にて t検定，X2 
検定，ロジスティック回帰モデルを用いて行った.
• ? ? ? ?
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Tab1e 4. Histo1ogica1 effects with respect to other factors 
Excellent Good Poor Statics 
Duration of therapy 7.9:!: 4.8 5.6士 2.4 4.6:!: 1.8 
J.<:xcel vs. J;'oor: p=0.003 
Excel vs. Good:-p=0.019 
Good vs. Poor: p=0.061 
Pre treatment PSA 42.7:!:65.4 51.8:!:62.4 4O.2:!:57.4 
J.<:xcel vs. J;'oor: p=0.451 
Excel vs. Good:-p=0.326 
Good vs. Poor: p=0.263 
Excel vs. Poor: p=0.414 
Number ofpositive core 3.2土1.9 3.2:!: l.l 3.1:!: 1.4 Excel vs. (;ood: p=0.412 
Good vs. Poor: p=0.475 
G3/excellent responder (n=17); G2/good responder (n=26); GO， Gl/poor r回ponder(n=19). 
Tab1e 5. Predictive factors for maximum 










Duration of treat 0.004 
Biopsy moderate紳 0.375
poor*地 0.779
No. of positive core 0.626 
* vs. T2，料 vs.Well. Logistic regression 
test 






























































る12.13) その理由として G1eaveらは 14) ネオア
ジュパント療法初期にアンドロゲン遮断による PSA
産生の停止やアポトーシスにより PSAが急減し，そ


























にもかかわらず治療効果 grade0， margin positive 
の症例も散見された.今回のネオアジュパント療法に
よる組織学的治療効果の検討では，観察期間は短いも
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